A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

NCT06355661 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Upper Respiratory Tract Infections

Interventions

DIETARY_SUPPLEMENT: ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule
DIETARY_SUPPLEMENT: MCC: 400 mg (± 10%) per Capsule

Sponsor

Vedic Lifesciences Pvt. Ltd.